Delineating the important molecular pathways in carcinogenesis has helped d
evelop and advance the field of molecular diagnosis. Bladder cancer has ser
ved as an excellent model in translating some of the advances from the labo
ratory to clinical settings. Many investigators have examined the use of p5
3 to help manage patients with bladder cancer who are at high risk of tumor
progression. This article reviews the clinical studies that have used p53
as a marker in bladder carcinoma and concludes by determining whether routi
ne assessment of the p53 tumor suppressor gene/protein is indicated at this
time.